RecruitingNCT06989216
Multi-modal Quantitative Imaging of the Skin
DermaFlow Alpha - Multi-modal Quantitative Imaging of the Skin
Sponsor
HJN Sverige AB/Neko Health
Enrollment
8,000 participants
Start Date
Feb 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This clinical trial is about evaluating the suitability of multi-modal imaging technology, which covers virtually the entire body, to evaluate the possibility of screening and early detection of disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.
- Patients with signed informed consent
Exclusion Criteria6
- Cognitive impairment
- Patients unable to understand the oral and written study information in Swedish or English
- Other severe disorder or terminal disease
- Patients unable to provide an informed consent
- Patients not able to keep balance, while standing up with closed eyes, without any aid
- Claustrophobic patients
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06989216
Related Trials
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT0381634552 locations
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
NCT062987342 locations
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
NCT040681552 locations
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
NCT045341271 location